It is generally known that the IDH1mutation has a significant effect on the prognosis of glioma patients.14 However, patients with IDH1 mutations only showed a better PFS compared with IDH1 wildtype patients in sGBM (Figure 3A and B). This evidence concerns the gene IDH1 and central nervous system cancer.